PerkinElmer, Inc. (PKI) and Axxam srl to Deliver Advanced Screening Solutions for Drug Discovery
5/22/2007 11:53:38 AM
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, today announced that it signed a worldwide licensing agreement with Axxam SpA, a Milan, Italy-based company focused on early-stage discovery research and services for the life science industry, to become the exclusive provider of Axxam’s Photina® photoprotein technology to the drug discovery market. The Photina® technology is a luminescent cell-based assay platform optimized for screening important drug discovery targets, including G-protein coupled receptors (GPCRs) and ion channels. The terms of the agreement also provide for a formal research and development program between PerkinElmer and Axxam to develop additional Photina® GPCR and ion channel cell lines for use in high throughput screening and compound profiling. Axxam retains the rights to use the technology for its discovery services to third parties.
comments powered by